Cargando…
Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives
Pancreatic cancer is the fourth leading cause of cancer-related death in the USA and Europe; early symptoms and screenings are lacking, and it is usually diagnosed late with a poor prognosis. Circulating tumor cells (CTCs) have been promising new biomarkers in solid tumors. In the last twenty years...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895979/ https://www.ncbi.nlm.nih.gov/pubmed/31717773 http://dx.doi.org/10.3390/cancers11111659 |
_version_ | 1783476677285773312 |
---|---|
author | Martini, Verena Timme-Bronsert, Sylvia Fichtner-Feigl, Stefan Hoeppner, Jens Kulemann, Birte |
author_facet | Martini, Verena Timme-Bronsert, Sylvia Fichtner-Feigl, Stefan Hoeppner, Jens Kulemann, Birte |
author_sort | Martini, Verena |
collection | PubMed |
description | Pancreatic cancer is the fourth leading cause of cancer-related death in the USA and Europe; early symptoms and screenings are lacking, and it is usually diagnosed late with a poor prognosis. Circulating tumor cells (CTCs) have been promising new biomarkers in solid tumors. In the last twenty years (1999–2019), 140 articles have contained the key words “Circulating tumor cells, pancreatic cancer, prognosis and diagnosis.” Articles were evaluated for the use of CTCs as prognostic markers and their correlation to survival in pancreatic ductal adenocarcinoma (PDAC). In the final selected 17 articles, the CTC detection rate varied greatly between different enrichment methodologies and ranged from 11% to 92%; the majority of studies used the antigen-dependent CellSearch(©) system for CTC detection. Fifteen of the reviewed studies showed a correlation between CTC presence and a worse overall survival. The heterogeneity of CTC-detection methods and the lack of uniform results hinder a comparison of the evaluated studies. However, CTCs can be detected in pancreatic cancer and harbor a hope to serve as an early detection tool. Larger studies are needed to corroborate CTCs as valid biomarkers in pancreatic cancer. |
format | Online Article Text |
id | pubmed-6895979 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68959792019-12-24 Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives Martini, Verena Timme-Bronsert, Sylvia Fichtner-Feigl, Stefan Hoeppner, Jens Kulemann, Birte Cancers (Basel) Review Pancreatic cancer is the fourth leading cause of cancer-related death in the USA and Europe; early symptoms and screenings are lacking, and it is usually diagnosed late with a poor prognosis. Circulating tumor cells (CTCs) have been promising new biomarkers in solid tumors. In the last twenty years (1999–2019), 140 articles have contained the key words “Circulating tumor cells, pancreatic cancer, prognosis and diagnosis.” Articles were evaluated for the use of CTCs as prognostic markers and their correlation to survival in pancreatic ductal adenocarcinoma (PDAC). In the final selected 17 articles, the CTC detection rate varied greatly between different enrichment methodologies and ranged from 11% to 92%; the majority of studies used the antigen-dependent CellSearch(©) system for CTC detection. Fifteen of the reviewed studies showed a correlation between CTC presence and a worse overall survival. The heterogeneity of CTC-detection methods and the lack of uniform results hinder a comparison of the evaluated studies. However, CTCs can be detected in pancreatic cancer and harbor a hope to serve as an early detection tool. Larger studies are needed to corroborate CTCs as valid biomarkers in pancreatic cancer. MDPI 2019-10-26 /pmc/articles/PMC6895979/ /pubmed/31717773 http://dx.doi.org/10.3390/cancers11111659 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Martini, Verena Timme-Bronsert, Sylvia Fichtner-Feigl, Stefan Hoeppner, Jens Kulemann, Birte Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives |
title | Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives |
title_full | Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives |
title_fullStr | Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives |
title_full_unstemmed | Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives |
title_short | Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives |
title_sort | circulating tumor cells in pancreatic cancer: current perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895979/ https://www.ncbi.nlm.nih.gov/pubmed/31717773 http://dx.doi.org/10.3390/cancers11111659 |
work_keys_str_mv | AT martiniverena circulatingtumorcellsinpancreaticcancercurrentperspectives AT timmebronsertsylvia circulatingtumorcellsinpancreaticcancercurrentperspectives AT fichtnerfeiglstefan circulatingtumorcellsinpancreaticcancercurrentperspectives AT hoeppnerjens circulatingtumorcellsinpancreaticcancercurrentperspectives AT kulemannbirte circulatingtumorcellsinpancreaticcancercurrentperspectives |